Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
September 19, 2024 10:50 ET
|
Precede Biosciences, Inc.
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
September 15, 2024 06:05 ET
|
Precede Biosciences, Inc.
Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines in development Quantitative PSMA-PET...
Global Exosome Market Size, Forecast, Trials and Trends 2024: Exosome-Based Diagnostics and Therapeutics are Expanding, with 388 Clinical Trials Currently Underway
September 10, 2024 05:39 ET
|
Research and Markets
Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Global Exosome Market: Size, Forecast, Trials, and Trends, 2024" report has been added to ResearchAndMarkets.com's offering. Exosomes are...
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%
September 10, 2024 04:51 ET
|
Research and Markets
Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Gene Editing Therapeutics Market" report has been added to ResearchAndMarkets.com's offering.The gene editing therapeutics market is estimated to be...
New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
September 09, 2024 16:16 ET
|
Treos Bio Corp.
LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for...
Fimlab Is Adopting Proscia’s Software To Realize The Promise Of AI-Enabled Pathology
September 09, 2024 02:00 ET
|
Proscia
Fimlab Laboratories will use Proscia’s software platform to help its pathologists generate more precise results with artificial intelligence (AI).
Life Sciences Organizations Gain New Real-World Data Offering To Bring Precision Therapies And Diagnostics To Patients
September 04, 2024 08:00 ET
|
Proscia
Proscia customers can leverage over 10 million de-identified pathology images alongside corresponding clinical and genomic data
gRNA Industry Research Report 2024: Size, Share, Trends, Opportunities, and Forecasts, 2019-2029F
September 03, 2024 09:39 ET
|
Research and Markets
Dublin, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The "gRNA Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's...
Precision Medicine Market Report 2024: Comprehensive Data on Products, Technologies, Applications, End Users, Countries and Companies, 2024-2032, Featuring AstraZeneca, Bayer, bioMerieux, and More
September 02, 2024 09:41 ET
|
Research and Markets
Dublin, Sept. 02, 2024 (GLOBE NEWSWIRE) -- The "Precision Medicine Market Report, Forecast by Product, Technology, Application, End User, Countries and Company Analysis, 2024-2032" report has been...
DNA Sequencing Global Strategic Research Report 2024: Growing Adoption of Sequencing Services in Clinical Workflows Propels Market Growth - Global Forecast to 2030
August 29, 2024 10:50 ET
|
Research and Markets
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The "DNA Sequencing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for DNA Sequencing is...